Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy

Paul A. Gurbel; Udaya S. Tantry

doi:10.1038/nrcardio.2010.185

Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy

Paul A. Gurbel, Udaya S. Tantry

School of Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPis), whether itsclinical efficacy is reduced remains highly controversial. The Fda and European Medicines agency recommend that PPis and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.

Original language	English (US)
Pages (from-to)	7-8
Number of pages	2
Journal	Nature Reviews Cardiology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/nrcardio.2010.185
State	Published - Jan 2011

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1038/nrcardio.2010.185

Cite this

@article{b9dbc1a83d7e4b88ad9c903106b371ea,

title = "Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy",

abstract = "Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPis), whether itsclinical efficacy is reduced remains highly controversial. The Fda and European Medicines agency recommend that PPis and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.",

author = "Gurbel, {Paul A.} and Tantry, {Udaya S.}",

year = "2011",

month = jan,

doi = "10.1038/nrcardio.2010.185",

language = "English (US)",

volume = "8",

pages = "7--8",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Clopidogrel-PPI interaction, an ongoing controversy

AU - Gurbel, Paul A.

AU - Tantry, Udaya S.

PY - 2011/1

Y1 - 2011/1

N2 - Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPis), whether itsclinical efficacy is reduced remains highly controversial. The Fda and European Medicines agency recommend that PPis and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.

AB - Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPis), whether itsclinical efficacy is reduced remains highly controversial. The Fda and European Medicines agency recommend that PPis and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.

UR - http://www.scopus.com/inward/record.url?scp=78651517378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651517378&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2010.185

DO - 10.1038/nrcardio.2010.185

M3 - Article

C2 - 21170003

AN - SCOPUS:78651517378

SN - 1759-5002

VL - 8

SP - 7

EP - 8

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 1

ER -

Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this